Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 8/20 | 0.46 |
| ▸ | CDC42BPA | Q5VT25 | 8/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | PIM1 | P11309 | 3/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 3/20 | 0.43 |
| ▸ | FES | P07332 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 7/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.41 |
| ▸ | GSK3A | P49840 | 7/20 | 0.41 |
| ▸ | GSK3B | P49841 | 7/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.41 |
| ▸ | CSNK1G3 | Q9Y6M4 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12077055 | 0.86 | NAMPT (0.54) | ROCK1CDC42BPAAURKBCHEK2ROCK2 | |
| SCHEMBL12077158 | 0.86 | NAMPT (0.54) | ROCK1CDC42BPAAURKBCHEK2ROCK2 | |
| SCHEMBL4366215 | 0.82 | ROCK1 (0.55) | ROCK1CDC42BPAAURKBCHEK2ROCK2 | |
| SCHEMBL13277406 | 0.79 | NAMPT (0.44) | ROCK1CDC42BPAAURKBCHEK2ROCK2 | |
| SCHEMBL12076999 | 0.79 | ROCK1 (0.43) | ROCK1CDC42BPAAURKBCHEK2ROCK2 | |
| SCHEMBL12077354 | 0.78 | ROCK1 (0.43) | ROCK1CDC42BPAAURKBCHEK2ROCK2 | |
| SCHEMBL12077957 | 0.78 | NAMPT (0.53) | ROCK1CDC42BPAAURKBCHEK2ROCK2 | |
| SCHEMBL12077914 | 0.78 | NAMPT (0.53) | ROCK1CDC42BPAAURKBCHEK2ROCK2 | |
| SCHEMBL12077917 | 0.78 | NAMPT (0.53) | ROCK1CDC42BPAAURKBCHEK2ROCK2 | |
| SCHEMBL1834699 | 0.78 | ROCK1 (0.43) | ROCK1CDC42BPAAURKBCHEK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | claimed |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| WO-2010142735-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TOPOTARGET A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | NAMPT, NAPRT, NNT | ROCK1 3563/4885CDC42BPA 1979/4885AURKB 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.